Compare TRMK & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRMK | IBRX |
|---|---|---|
| Founded | 1889 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 1987 | N/A |
| Metric | TRMK | IBRX |
|---|---|---|
| Price | $40.25 | $2.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $42.67 | $9.71 |
| AVG Volume (30 Days) | 304.9K | ★ 13.4M |
| Earning Date | 01-27-2026 | 11-04-2025 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | ★ 10.82 | N/A |
| EPS | ★ 3.66 | N/A |
| Revenue | ★ $773,338,000.00 | $82,555,000.00 |
| Revenue This Year | $58.33 | $667.18 |
| Revenue Next Year | $4.57 | $93.03 |
| P/E Ratio | $10.95 | ★ N/A |
| Revenue Growth | 55.58 | ★ 1025.95 |
| 52 Week Low | $29.77 | $1.83 |
| 52 Week High | $41.43 | $4.27 |
| Indicator | TRMK | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.61 | 50.31 |
| Support Level | $38.47 | $1.95 |
| Resistance Level | $40.56 | $2.29 |
| Average True Range (ATR) | 0.70 | 0.10 |
| MACD | -0.13 | -0.00 |
| Stochastic Oscillator | 60.21 | 57.47 |
Trustmark Corp is a bank holding company. Through its subsidiaries, the company operates as a financial services organization providing banking and other financial solutions in Alabama, Florida, Mississippi, Tennessee, and Texas. Its principal products and services include Commercial Banking, Consumer Banking, Mortgage Banking, Insurance, Wealth Management and Trust Services, and others. The company is managed along two operating segments: General Banking and Wealth Management. The General Banking segment, which generates the majority of the revenue, provides all traditional banking products and services, including loan deposits, and also consists of internal operations.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.